CXCL17 and breast cancer: In breast cancer and colon tumor, CXCL17 is coregulated with vascular endothelial growth factor (VEGF) and it increases vasculature in vivo, suggesting that it might promote tumor progression by enhancing angiogenesis [17]–[19].